Boundless Bio, Inc. Common Stock (BOLD) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.17x
Boundless Bio, Inc. Common Stock (BOLD) has a Cash Flow-to-Debt Ratio of -0.17x as of September 2025, meaning its operating cash flow of $-10.20 Million could theoretically repay 0% of its total liabilities ($58.55 Million) in one year. See BOLD free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.17x
Operating CF / Total Liabilities
Operating Cash Flow
$-10.20 Million
USD
Total Liabilities
$58.55 Million
USD
Data as of
Sep 2025
Most recent filing
Boundless Bio, Inc. Common Stock Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Boundless Bio, Inc. Common Stock across 7 annual periods. For the full cash flow conversion analysis, see how efficiently does Boundless Bio, Inc. Common Stock generate cash.
Annual Cash Flow-to-Debt Ratio for Boundless Bio, Inc. Common Stock (2016–2024)
Year-by-year debt coverage analysis for Boundless Bio, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.09x | $-60.84 Million | $55.77 Million | ▼ -498.4% |
| 2023 | -0.18x | $-46.85 Million | $256.98 Million | ▲ +27.0% |
| 2022 | -0.25x | $-39.60 Million | $158.53 Million | ▼ -63.2% |
| 2021 | -0.15x | $-23.25 Million | $151.91 Million | ▲ +95.8% |
| 2018 | -3.62x | $-107.98 Million | $29.80 Million | ▲ +5.4% |
| 2017 | -3.83x | $-84.51 Million | $22.06 Million | ▼ -77.3% |
| 2016 | -2.16x | $-49.02 Million | $22.69 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.